Health
Biogen and Ionis Report 38% Slower Alzheimer’s Decline with Diranersen at Two Years, but Phase 3 Must Confirm Results
Biogen and Ionis Pharmaceuticals have reported two-year findings from the Phase 2 CELIA study of diranersen, an investigational antisense oligonucleotide…